One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey

A.G. Bejinariu*, H. Makimoto, R. Wakili, S. Mathew, J. Kosiuk, D. Linz, J. Steinfurt, D.G. Dechering, C. Meyer, C. Veltmann, M. Kelm, G. Frommeyer, L. Eckardt, T. Deneke, D. Duncker, P. Muller

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Introduction:Periprocedural oral anticoagulation (OAC) strategies for atrial fibrillation (AF) ablation procedures are changing rapidly.Objective:To assess the management and course of periprocedural OAC for AF ablation procedures in experienced electrophysiology (EP) centers in Germany over the last 12 months.Methods:The data are based on an electronic questionnaire, which was sent to 35 experienced EP centers in September 2018 and then exactly 1 year later. Participants provided information on their periprocedural OAC management, the handling with dual therapy (OAC plus single antiplatelet therapy), the availability of specific antidotes, the transseptal puncture approach, and noteworthy complications.Results:Responses were received from all 35 centers and represent 10,010 AF ablation procedures annually. In 2018, the administration of vitamin K antagonist (VKA) was continued throughout the procedure at all centers (100%). In contrast, the majority of centers used minimally interrupted periprocedural non-vitamin K antagonist oral anticoagulants (NOAC) (54.3%), 13 centers (37.2%) completely interrupted NOAC, and only 3 centers (8.5%) continued NOAC throughout the procedure. At the 1-year follow-up survey, 32 centers were found to have continued their previous strategy of periprocedural OAC and 3 changed from a minimally interrupted to a continued NOAC strategy. Of note, 30 centers (85.7%) performed transseptal puncture fluoroscopically without additional cardiac imaging. In the setting of uninterrupted periprocedural OAC management, no relevant complications were noted.Conclusion:Our survey shows marked heterogeneous periprocedural OAC management at experienced EP centers in Germany. Whereas continuation of VKA has already been integrated into clinical practice, the majority of centers still use a minimally interrupted NOAC strategy.
Original languageEnglish
Pages (from-to)676-681
Number of pages6
Issue number10
Publication statusPublished - 1 Oct 2020


  • atrial fibrillation ablation
  • catheter ablation
  • complications
  • management
  • oral anticoagulation
  • periprocedural strategy
  • survey
  • warfarin
  • Atrial fibrillation ablation
  • Periprocedural strategy
  • Survey
  • Oral anticoagulation

Cite this